Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) - Stock Valuation and Financial Performance

BSE: 500676 | NSE: GSKCONS | Consumer Food | Mid Cap

Glaxo.Cons. Health Share Price

9,696.40 0.00 0.00%
as on 15-Apr'20 18:01

DeciZen - make an informed investing decision on Glaxo.Cons. Health

M-Cap below 100cr DeciZen not available

Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) stock performance -

mw4me loader
P/E Ratio (SA):
39.13
Market Cap:
45,225.1 Cr.
52-wk low:
10,394.1
52-wk high:
10,845.8

Is an attractive stock to invest in?

1. Is a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) is a good quality company.

2. Is undervalued or overvalued?

The key valuation ratios of Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)'s currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Glaxo.Cons. Health:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19TTM
ROCE % 28.3%32.3%33.7%34.7%42.3%29.8%27.7%22.1%21.1%25.8%-
Value Creation
Index
1.11.41.51.62.11.71.51.00.91.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,9222,3062,7653,1873,8954,3084,1363,9914,3174,7824,984
Sales YoY Gr.-20%19.9%15.3%22.2%10.6%-4%-3.5%8.2%10.8%-
Adj EPS 55.471.283.8102.9127.4138.9161.7155.5165.3232.3274.8
YoY Gr.-28.5%17.7%22.7%23.9%9%16.4%-3.8%6.3%40.6%-
BVPS (₹) 215.2228.3272.1323.6344.9502.4665.5742.5828.7973.71,055.4
Adj Net
Profit
2332993524335365846806546959771,156
Cash Flow from Ops. 400326391554516611573603723671-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.7%4.2%5%10.8%
Adj EPS 17.3%12.8%12.8%40.6%
BVPS18.3%23.1%13.5%17.5%
Share Price 8.5% 6.1% -3.4% -9.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19TTM
Return on
Equity %
2832.133.534.542.229.827.722.12125.827.1
Op. Profit
Mgn %
16.316.418.2181817.220.32120.523.925.4
Net Profit
Mgn %
12.11312.813.613.813.616.416.416.120.423.2
Debt to
Equity
0000000000-
Working Cap
Days
178157170118115223250294324332181
Cash Conv.
Cycle
3-12-12-14-14-18-33-43-53-50120

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)

Standalone Consolidated
TTM EPS (₹) 274.8 -
TTM Sales (₹ Cr.) 4,984 -
BVPS (₹.) 1,055.4 -
Reserves (₹ Cr.) 4,396 -
P/BV 10.19 -
PE 39.13 -
From the Market
52 Week Low / High (₹) 10394.05 / 10845.75
All Time Low / High (₹) 93.75 / 11290.00
Market Cap (₹ Cr.) 45,225
Equity (₹ Cr.) 42.1
Face Value (₹) 10
Industry PE 65.3

Management X-Ray of Glaxo.Cons. Health:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Glaxo.Cons. Health

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSDec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Sales1,921.502,306.122,7653,187.494,868.574,307.594,136.273,991.284,316.524,782.01
Operating Expenses 1,610.911,929.402,260.552,614.083,995.813,577.503,298.113,152.973,433.163,641.04
Manufacturing Costs377.55430.27491.18549.96833.58731.24550.36498.76507.83556.02
Material Costs540.70678.11790.52917.581,373.301,180.141,066.341,053.541,177.911,148.91
Employee Cost 193.95221.86258.37301.12470.05431.29504.98450.86527.73644.62
Other Costs 498.72599.16720.48845.421,318.881,234.841,176.431,149.811,219.701,291.49
Operating Profit 310.59376.72504.45573.41872.76730.08838.16838.31883.361,140.97
Operating Profit Margin (%) 16.2%16.3%18.2%18.0%17.9%16.9%20.3%21.0%20.5%23.9%
Other Income 89.32117.3985.25113.79206.91221.89277.51239.06257.41432.60
Interest 4.032.603.472.421.050.742.282.782.030.78
Depreciation 42.0239.7145.9836.0862.5562.0957.4464.1864.3760.50
Exceptional Items 0000000000
Profit Before Tax 353.86451.80540.26648.691,016.07889.141,055.951,010.421,074.361,512.29
Tax 121.08151.95185.05211.93341.33305.54368.67353.74374.26529.49
Profit After Tax 232.78299.85355.21436.76674.75583.60687.28656.68700.10982.80
PAT Margin (%) 12.1%13.0%12.8%13.7%13.9%13.5%16.6%16.5%16.2%20.6%
Adjusted EPS (₹)55.471.384.5103.9160.4138.8163.4156.2166.5233.7
Dividend Payout Ratio (%)33%70%41%43%28%40%43%45%45%45%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSDec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19

Equity and Liabilities

Shareholders Fund 905.10960.041,144.171,360.981,812.852,113.042,798.703,122.673,485.124,094.71
Share Capital 42.0642.0642.0642.0642.0642.0642.0642.0642.0642.06
Reserves 863.04917.981,102.121,318.921,770.792,070.982,756.653,080.613,443.064,052.66
Minority Interest0000000000
Debt0000002.07000
Long Term Debt0000002.07000
Short Term Debt0000000000
Trade Payables285356.92359.37478.44671.59759.78785.18875.661,006.16952.61
Others Liabilities 776.741,146.741,465.64653.522,347.132,869.743,000.063,413.423,601.414,223.96
Total Liabilities 1,966.842,463.712,969.182,492.934,831.575,742.556,586.027,411.758,092.699,271.29

Fixed Assets

Gross Block558.48598.96636.66656.24854.621,059.28569.43629.35650.85696.76
Accumulated Depreciation364396.71435.97462.40514.71567.5488.16141.93175.32234.69
Net Fixed Assets194.48202.25200.69193.83339.91491.74481.28487.43475.53462.07
CWIP 37.79108.33149.16197.2438.4542.3151.3957.6738.2517.73
Investments 0000000000
Inventories266.03312369.96369.64407.42466.25461.62461.14409.42465.47
Trade Receivables31.3650.3799.19112.61299.35313.36354.16321278.72385.68
Cash Equivalents 819.80976.101,079.651,464.241,838.782,296.522,712.273,087.383,585.204,097.34
Others Assets617.39814.661,070.53155.371,907.672,132.362,525.302,997.143,305.573,843.01
Total Assets 1,966.842,463.712,969.182,492.934,831.575,742.556,586.027,411.758,092.699,271.29

Cash Flow

(All Figures are in Crores.)
PARTICULARSDec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Cash Flow From Operating Activity 399.99326.21390.73554.33644.50611.47573.46602.97723.04671.07
PBT 353.86451.80540.26648.691,016.07889.141,055.951,010.421,074.361,512.29
Adjustment 17.20-4.89-13.29-55.83-101.92-101.81-183.89-111.33-144.59-343.08
Changes in Working Capital 168.783944.69185.6763.23120.1353.4124.06260.211.38
Tax Paid -139.84-159.70-180.93-224.20-332.88-296-352-420.16-466.94-499.51
Cash Flow From Investing Activity -21.58-79.39-125.19-377.24-271.42330.69-151.58-602.40-446.45-335.06
Capex -45.27-108.63-95.25-81.88-167.51-105.66-52.13-65.72-49.41-32.66
Net Investments 000000-279.70-735.70-583.33-548.69
Others 23.6929.24-29.94-295.36-103.91436.35180.25199.02186.29246.29
Cash Flow From Financing Activity -29.59-90.53-248.06-175.47-222.70-222.15-285.59-361.33-363.40-376.80
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -4.77-2.45-2.86-4.40-1.29-0.74-2.28-2.78-2.03-0.78
Dividend Paid -21.25-75.50-210.28-147.19-189.25-189.25-231.31-294.23-293.09-311.18
Others -3.57-12.57-34.92-23.88-32.16-32.16-52.01-64.32-68.29-64.83
Net Cash Flow 348.82156.3017.481.61150.38720136.29-360.75-86.81-40.78
PARTICULARSDec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Ratios
ROE (%)27.9532.1533.7634.8742.5229.7327.9922.1821.1925.93
ROCE (%)42.9648.7351.6851.9864.0945.3342.9834.132.5439.92
Asset Turnover Ratio1.091.11.071.231.40.860.740.630.560.55
PAT to CFO Conversion(x)1.721.091.11.270.961.050.830.921.030.68
Working Capital Days
Receivable Days76911152527282525
Inventory Days49434340283537383633
Payable Days154173165167153221264288292311

Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) Stock News

Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Glaxo.Cons. Health on 15-Apr-2020 18:01 is ₹9,696.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Apr-2020 18:01 the market cap of Glaxo.Cons. Health stood at ₹45,225.1.
The latest P/E ratio of Glaxo.Cons. Health as of 15-Apr-2020 18:01 is 39.13.
The latest P/B ratio of Glaxo.Cons. Health as of 15-Apr-2020 18:01 is 10.19.
The 52-week high of Glaxo.Cons. Health is ₹10,845.8 and the 52-week low is ₹10,394.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glaxo.Cons. Health is ₹4,984 ( Cr.) .

About Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)

Glaxosmithkline Consumer Healthcare’s (GCH) core business is manufacturing of health drinks under the brand Horlicks. The history of the company goes way back in 1950s when bottled Horlicks was imported from England. But in the year 1955 due to change in import policy, import of Horlicks was stopped.

During 1956-57 a team of Horlicks visited India to explore possibilities for setting up a plant in India. For this the company approached Maharaja of Nabha, Pratap Singh in Punjab. Later in October 1958 with the support of Maharaja, Hindustan Milkfood Manufacturer (HMML) was established to produce Horlicks.

In the year 1969 Beecham plc acquired Horlicks England, which led the company to become major shareholder in HMML. In 1979 Beecham India was merged with Hindustan Milkfood Manufacturer. Later Beecham plc, UK got merged with SmithKline USA.

In January 2000 the name was changed to Glaxosmithkline Consumer Healthcare.

It exports products to countries like Bangladesh, Myanmar, Sri Lanka, Middle East, Fiji, Mauritius, Nepal, Bhutan and many more.

GCH has manufacturing plants located at Punjab, Andhra Pradesh, Haryana, Hyderabad, Chennai, Guwahati, Ghaziabad, Bangalore and Gurgaon.

Glaxosmithkline Consumer Healthcare has entered into an agreement with Laclede to purchase its dry mouth brand Biotene for $170 million.

In 2011 GSk has launched Sensodyne in an attempt to enter the Indian tooth paste market. "

Products

Nutritional drinks- Under this it manufactures and markets wide range of health drinks. Besides Horlicks, it has created brands like, Boost, Maltova and Viva. Apart from youth, it also caters to other consumers like mothers with Mother’s Horlicks and Horlicks Lite for diabetic consumers.

OTC Products- It promotes and distributes over the counter drugs like pain relief balm -- Iodex, pain relief tablet and syrup -- Crocin and drug for acidity problems -- Eno.

The company’s nutritional food services division has also developed vending of Boost and Horlicks. Around 500 vending machine have been placed in corporates, schools and hospitals.

Award and Recognition

It manufacturing plants have received various certification for its quality and health and safety systems such as OHSAS 18001, ISO 9001:2000 and ISO 14001:2004 by DNV and SA8000.

The company’s Sonepat factory has won the prestigious “National Energy Conservation Award – 2007” from the President of India in the Food Processing Sector.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.